|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0036429,
umls-concept:C0065477,
umls-concept:C0087111,
umls-concept:C0181904,
umls-concept:C0521316,
umls-concept:C0596972,
umls-concept:C0728873,
umls-concept:C0855152,
umls-concept:C1516615,
umls-concept:C1521743,
umls-concept:C1522449,
umls-concept:C1522718,
umls-concept:C1704646
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1999-11-30
|
|
pubmed:abstractText |
To evaluate the efficacy of a combined modality treatment (MACOP-B plus mediastinal radiotherapy) and the advantages of Gallium-67-citrate single-photon emission ((67)GaSPECT) over computed tomography (CT) for restaging in patients with primary mediastinal large B-cell lymphoma (PMLBCL) with sclerosis. Between 1989 and 1998, 50 previously untreated patients with PMLBCL with sclerosis (70% with bulky mass) were treated with MACOP-B regimen plus mediastinal radiotherapy. The radiologic clinical stage with evaluation of tumor size included CT and (67)GaSPECT at diagnosis, after chemotherapy, and after radiotherapy. Forty-three patients (86%) achieved a complete response and 7 were nonresponders to treatment. For the imaging evaluation, only 47 patients were evaluable because 3 had disease progression during chemotherapy. After treatment, 3/5 (60%) patients with positive (67)GaSPECT and negative CT scan relapsed, as against 0/21 (0%) with negative (67)GaSPECT and CT scan. Twenty-one patients had a positive CT scan: of these, the 4 with positive (67)GaSPECT all progressed, whereas there were no relapses among the 17 with negative (67)GaSPECT. After radiotherapy, there was a decrease of positive CT (from 33 to 21 cases) and of positive (67)GaSPECT (from 31 to 9 cases). Relapse-free survival rate was 93% at 96 months (median 39 months). In patients with PMLBCL with sclerosis, MACOP-B plus radiation therapy is a very useful first-line treatment and radiation therapy may play an important role. As regards restaging, (67)GaSPECT should be considered the imaging technique of choice at least in patients who show CT positivity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0006-4971
|
|
pubmed:author |
pubmed-author:AscaniSS,
pubmed-author:BendandiMM,
pubmed-author:MagagnoliMM,
pubmed-author:MandelliFF,
pubmed-author:MartelliM PMP,
pubmed-author:MartelliMM,
pubmed-author:OrcioniG FGF,
pubmed-author:PalombiFF,
pubmed-author:PescarmonaEE,
pubmed-author:PileriS ASA,
pubmed-author:ScaramucciLL,
pubmed-author:TuraSS,
pubmed-author:ZinzaniP LPL
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3289-93
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:10552937-Adult,
pubmed-meshheading:10552937-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10552937-Bleomycin,
pubmed-meshheading:10552937-Citrates,
pubmed-meshheading:10552937-Combined Modality Therapy,
pubmed-meshheading:10552937-Cyclophosphamide,
pubmed-meshheading:10552937-Doxorubicin,
pubmed-meshheading:10552937-Female,
pubmed-meshheading:10552937-Gallium,
pubmed-meshheading:10552937-Humans,
pubmed-meshheading:10552937-Lymphoma, B-Cell,
pubmed-meshheading:10552937-Male,
pubmed-meshheading:10552937-Mediastinal Neoplasms,
pubmed-meshheading:10552937-Methotrexate,
pubmed-meshheading:10552937-Middle Aged,
pubmed-meshheading:10552937-Prednisolone,
pubmed-meshheading:10552937-Prospective Studies,
pubmed-meshheading:10552937-Sclerosis,
pubmed-meshheading:10552937-Survival Analysis,
pubmed-meshheading:10552937-Tomography, Emission-Computed, Single-Photon,
pubmed-meshheading:10552937-Vincristine
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients.
|
|
pubmed:affiliation |
Institute of Hematology and Medical Oncology "Seràgnoli," University of Bologna, Bologna, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
